Dipeptidyl-Peptidase IV inhibitors and glycemic control in type 2 Diabetes Mellitus

Authors

  • Lokendra Bahadur Sapkota Department of Biochemistry, Chitwan Medical College, Bharatpur
  • Sangita Thapa Department of Microbiology, Chitwan Medical College, Bharatpur

DOI:

https://doi.org/10.3126/jcmsn.v12i1.14684

Abstract

Background & Objectives: Type 2 diabetes mellitus (T2DM) is a progressive disease, characterized by insulin resistance, impaired glucose-induced insulin secretion, inappropriately elevated glucagon concentrations, and hyperglycemia. Many patients cannot obtain satisfactory glycemic control with current therapies. New and more effective agents, targeted not only at treatment, but also at prevention of the disease, its progression, and its associated complications, are, therefore, required. The dipeptidyl peptidase-4 (DPP-4) inhibitors are a newer class of oral drugs for the treatment of T2DM. They inhibit the breakdown of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) thereby increasing the incretin effect in patients with T2DM. In clinical practice they are associated with significant reductions in HbA1c, no weight gain and a low risk of hypoglycemia. Since incretin response is markedly diminished in Asian populations, these agents can be used to achieve satisfactory glycemic control in Nepalese T2DM patients.

JCMS Nepal. 2016;12(1):28-32.

Downloads

Download data is not yet available.
Abstract
1178
PDF
606

Downloads

Published

2016-03-31

How to Cite

Sapkota, L. B., & Thapa, S. (2016). Dipeptidyl-Peptidase IV inhibitors and glycemic control in type 2 Diabetes Mellitus. Journal of College of Medical Sciences-Nepal, 12(1), 28–32. https://doi.org/10.3126/jcmsn.v12i1.14684

Issue

Section

Review Articles